LOCID). The aim of the study was to assess the severity of CVID using the ''AS'', which focuses mainly on cumulative damage to organs such as result of infections, autoimmunity or inflammation. METHODS: We retrospectively study charts of patients with CVID, seen at a Reference Center, and applied the "AS". The score is based on the severity of the complications of each organ, classified as mild 5 1point (without long-term morbidity), moderate 5 5points (short and long-term morbidity) and severe 5 10points (fatal or with the potential to severe disability). RESULTS: We evaluated 29 charts (69% male), with a median of age 36.3 y. The lung was the most affected organ, with manifestations in 69%, mainly bronchiectasis (58.6%). Gastrointestinal complications such as severe enteritis were the second most frequent (20.7%). Autoimmune manifestations were present in 41.4%, mainly cytopenias. Three patients had some type of malignancy. The total score in the analyzed population ranged from 0 to 47. Patients with a score above 35 had CD4 lymphopenia during evolution in 75% of cases. CONCLUSIONS: The "AS'' can be a useful tool for the identification of patients with LOCID, in addition to providing a linear assessment of the evolution of each patient, as well as a strategy until the genetic clarification to differentiate the CVID from the monogenic CIVD-like.

No abstract